行情

EDIT

EDIT

Editas Medicine
NASDAQ

实时行情|Nasdaq Last Sale

22.66
-0.33
-1.44%
已收盘, 16:41 11/14 EST
开盘
23.06
昨收
22.99
最高
23.26
最低
22.24
成交量
54.03万
成交额
--
52周最高
32.46
52周最低
17.80
市值
11.22亿
市盈率(TTM)
-10.6355
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EDIT 新闻

  • Editas adds to Celgene collaboration-stoked up move, shares ahead 4%
  • Seeking Alpha - Article.1天前
  • Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
  • Zacks.1天前
  • Editas Expands Its Celgene Partnership After Another Strong Quarter
  • MotleyFool.com.1天前
  • Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.2天前

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

EDIT 简况

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
展开

Webull提供Editas Medicine Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。